BioCryst Pharmaceuticals BCRX ORLADEYO — Royalty purchase agreement, royalties paid and payable
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept bcrx:RoyaltyPurchaseAgreementRoyaltiesPaidAndPayable.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's orladeyo — royalty purchase agreement, royalties paid and payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's ORLADEYO — royalty purchase agreement, royalties paid and payable?
- BioCryst Pharmaceuticals (BCRX) reported ORLADEYO — royalty purchase agreement, royalties paid and payable of $103.41M in Q1 2026.
- What does ORLADEYO — royalty purchase agreement, royalties paid and payable mean?
- This metric tracks the total financial obligations and payments made to third parties under royalty purchase or monetization agreements related to a specific pharmaceutical product. It reflects the cost of capital associated with external funding arrangements where future product revenues are shared with investors or partners. Monitoring this figure is essential for assessing the net economic benefit retained by the company from its commercialized assets.